TEAD-targeting small molecules induce a cofactor switch to regulate the Hippo pathway

A Alissa D. Guarnaccia (Department of Proteomic and Genomic Technologies, Genentech) T Thijs J. Hagenbeek (Department of Discovery Oncology, Genentech) W Wendy Lee (Department of Discovery Chemistry, Genentech) N Noelyn Kljavin (Department of Molecular Oncology, Genentech) M Meena Choi (Department of Proteomic and Genomic Technologies, Genentech) B Benjamin Tombling (Department of Early Discovery Biochemistry, Genentech) C Carsten Peukert (Department of Discovery Chemistry, Genentech) G Gözde Ulas (Department of Biochemical and Cellular Pharmacology, Genentech) V Vasumathi Kameswaran D Daniel Le (Department of Proteomic and Genomic Technologies, Genentech) S Sayantanee Paul (Department of Discovery Oncology, Genentech) S Samir Vaidya (Department of Proteomic and Genomic Technologies, Genentech) J Jason R. Zbieg (Department of Discovery Chemistry, Genentech) J James J. Crawford (Department of Discovery Chemistry, Genentech) B Bence Daniel (Department of Pathology, Stanford University) A Anwesha Dey (Department of Discovery Oncology, Genentech) J Jennie R. Lill (Department of Proteomic and Genomic Technologies, Genentech)

Abstract

TEAD proteins are the main transcriptional effectors of the Hippo signaling pathway and a clinical-stage pharmacological target in oncology. Most TEAD-targeting small molecules are designed to disrupt interaction between TEAD and the oncogenic transcriptional activators YAP and TAZ. Here, we uncover an alternative mechanism for a subset of TEAD lipid pocket-binding molecules. We report that select sulfonamide-containing TEAD-targeting compounds enhance the interaction between TEAD and the transcriptional repressor VGLL4. Chemically induced VGLL4–TEAD complexes confer an antiproliferative effect by outcompeting YAP–TEAD complexes at chromatin. This cofactor switch from YAP to VGLL4 impacts transcriptional networks, including influencing the expression of genes involved in cellular proliferation and mechanosignaling. We demonstrate that VGLL4 is required for an antiproliferative response to these sulfonamide-containing compounds by counteracting YAP. We show that VGLL4 overexpression can confer sensitivity to these compounds in Hippo-driven cell lines, and we further show that genetic deletion of VGLL4 oblates cellular responsiveness to these molecules in cells and in vivo. Our data reveal a category of TEAD inhibitors that act as “molecular glues” toward the repressive VGLL4–TEAD interaction. These findings open up understandings for curbing the oncogenic activity of Hippo pathway deregulation in cancer, and identify glue-like molecules that promote transcriptional repression.

Article Details

Volume / Issue Vol. 122, Issue 27
Published July 08, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (17)

A

Alissa D. Guarnaccia

Department of Proteomic and Genomic Technologies, Genentech

T

Thijs J. Hagenbeek

Department of Discovery Oncology, Genentech

W

Wendy Lee

Department of Discovery Chemistry, Genentech

N

Noelyn Kljavin

Department of Molecular Oncology, Genentech

M

Meena Choi

Department of Proteomic and Genomic Technologies, Genentech

B

Benjamin Tombling

Department of Early Discovery Biochemistry, Genentech

C

Carsten Peukert

Department of Discovery Chemistry, Genentech

G

Gözde Ulas

Department of Biochemical and Cellular Pharmacology, Genentech

V

Vasumathi Kameswaran

D

Daniel Le

Department of Proteomic and Genomic Technologies, Genentech

S

Sayantanee Paul

Department of Discovery Oncology, Genentech

S

Samir Vaidya

Department of Proteomic and Genomic Technologies, Genentech

J

Jason R. Zbieg

Department of Discovery Chemistry, Genentech

J

James J. Crawford

Department of Discovery Chemistry, Genentech

B

Bence Daniel

Department of Pathology, Stanford University

A

Anwesha Dey

Department of Discovery Oncology, Genentech

J

Jennie R. Lill

Department of Proteomic and Genomic Technologies, Genentech